Integrative model of chronically activated immune-hormonal pathways important in the generation of fibromyalgia

British Journal of Medical Practitioners

Volumn 5, Issue 3, 2012, Pages 524-

  Breeding, Paul C ^a   Russell, Nancy C ^a   Nicolson, Garth L ^a  

^a The Institute for Molecular Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; DULOXETINE; GROWTH HORMONE; HYDROCORTISONE; INSULIN; LEPTIN; MILNACIPRAN; NORADRENALIN; SEROTONIN; THYROID HORMONE; TOXIN;

ARTICLE; AUTOIMMUNITY; BACTERIAL INFECTION; CHRONIC FATIGUE SYNDROME; CHRONIC PAIN; CONNECTIVE TISSUE; FATIGUE; FIBROMYALGIA; HORMONAL REGULATION; HORMONE ACTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSTIMULATION; INJURY; METABOLIC SYNDROME X; NERVOUS SYSTEM; NEUROPATHIC PAIN; OXIDATIVE STRESS; PSYCHOTRAUMA; SYMPTOM; UPREGULATION; VIRUS INFECTION;

EID: 84868283802     PISSN: 17578515     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (105)

1. Anonymous. Centers for Disease Control: Fibromyalgia 2012: Available from: http://www.cdc.gov/arthritis/basics/fibromyalgia.htm.
2. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33(2):160-72.
3. Wolfe F, Clauw DJ, Fitzcharles MA, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011;38(6):1113-22.
4. Rehm SE, Koroschetz J, Gockel U, et al. A cross-sectional survey of 3035 patients with fibromyalgia: subgroups of patients with typical comorbidities and sensory symptom profiles. Rheumatology. 2010;49(6):1146-52.
5. Gran JT. The epidemiology of chronic generalized musculoskeletal pain. Best Pract Res Clin Rheumatol. 2003;17(4):547-61.
6. Yunus MB. Gender differences in fibromyalgia and other related syndromes. J Gend Specif Med. 2002;5(2):42-7.
7. Macfarlane TV, Blinkhorn A, Worthington HV, et al. Sex hormonal factors and chronic widespread pain: a population study among women. Rheumatology (Oxford). 2002;41(4):454-7.
8. Samborski W, Sobieska M, Pieta P, et al. Normal profile of sex hormones in women with primary fibromyalgia. Ann Acad Med Stetin. 2005;51(2):23-6.
9. Okifuji A, Turk DC. Sex hormones and pain in regularly menstruating women with fibromyalgia syndrome. J Pain. 2006;7(11):851-9.
10. Arnold LM, Hudson JI, Hess EV, et al. Family study of fibromyalgia. Arthritis and rheumatism. 2004;50(3):944-52.
11. Neumann L, Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Rep. 2003;7(5):362-8.
12. Endresen GK. Mycoplasma blood infection in chronic fatigue and fibromyalgia syndromes. Rheumatol Int. 2003;23(5):211-5.
13. Stratton CW, Sriram S. Association of Chlamydia pneumoniae with central nervous system disease. Microbes Infect. 2003;5(13):1249-53.
14. Chia JK, Chia LY. Chronic Chlamydia pneumoniae infection: a treatable cause of chronic fatigue syndrome. Clin Infect Dis. 1999;29(2):452-3.
15. Nicolson GL, Gan R, Haier J. Multiple co-infections (Mycoplasma, Chlamydia, human herpes virus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms. APMIS. 2003;111(5):557-66.
16. Nicolson GL, Gan R, Haier J. Evidence for Brucella spp. and Mycoplasma spp. co-infections in blood of chronic fatigue syndrome patients. J of Chronic Fatigue Syndrome. 2005;12(2):5-17.
17. Nicolson GL, Nasralla MY, De Meirleir K, et al. Evidence for Bacterial (Mycoplasma, Chlamydia) and Viral (HHV-6) Co-Infections in Chronic Fatigue Syndrome Patients. Journal of Chronic Fatigue Syndrome. 2003;11 (2):7-19.
18. Nicolson GL, Nicolson NL, Haier J. Chronic fatigue syndrome patients subsequently diagnosed with Lyme disease Borrelia burgdorferi: Evidence for Mycoplasma species co-infections. J of Chronic Fatigue Syndrome. 2008;14(4):5-17.
19. Nicolson GL, Nicolson NL. Gulf War illnesses: complex medical, scientific and political paradox. Med Confl Surviv. 1998;14(2):156-65.
20. Vojdani A, Choppa PC, Tagle C, et al. Detection of Mycoplasma genus and Mycoplasma fermentans by PCR in patients with Chronic Fatigue Syndrome. FEMS Immunol Med Microbiol. 1998;22(4):355-65.
21. Nasralla M, Haier J, Nicolson GL. Multiple mycoplasmal infections detected in blood of patients with chronic fatigue syndrome and/or fibromyalgia syndrome. Eur J Clin Microbiol Infect Dis. 1999;18(12):859-65.
22. Nasralla MY, Haier J, Nicolson NL, et al. Examination of mycoplasmas in blood of 565 chronic illness patients by polymerase chain reaction. Int J Med Biol Environ. 2000;28(1):15-23.
23. Nijs J, Nicolson GL, De Becker P, et al. High prevalence of Mycoplasma infections among European chronic fatigue syndrome patients. Examination of four Mycoplasma species in blood of chronic fatigue syndrome patients. FEMS Immunol Med Microbiol. 2002;34(3):209-14.
24. Vernon SD, Shukla SK, Conradt J, et al. Analysis of 16S rRNA gene sequences and circulating cell-free DNA from plasma of chronic fatigue syndrome and non-fatigued subjects. BMC Microbiol. 2002;2:39.
25. Komaroff AL, Goldenberg D. The chronic fatigue syndrome: definition, current studies and lessons for fibromyalgia research. J Rheumatol Suppl. 1989;19:23-7.
26. De Meirleir K, De Becker P, Nijs J, et al. Chronic fatigue syndrome etiology, the immune system and infection. In: Englebienne P, De Meirleir K, editors. Chronic fatigue Syndrome: A biological approach. Boca Raton, Florida: CRC Press; 2002. p. 201-28.
27. Ablin JN, Shoenfeld Y, Buskila D. Fibromyalgia, infection and vaccination: two more parts in the etiological puzzle. J Autoimmun. 2006;27(3):145-52.
28. Nicolson GL, Haier J. Role of chronic bacterial and viral infections in neurodegenerative, neurobehavioral, psychiatric, autoimmune and fatiguing illnesses: Part 2. BJMP. 2010;3(1).
29. Wallace DJ, Hallegua DS. Fibromyalgia: the gastrointestinal link. Curr Pain Headache Rep. 2004;8(5):364-8.
30. Othman M, Aguero R, Lin HC. Alterations in intestinal microbial flora and human disease. Curr Opin Gastroenterol. 2008;24(1):11-6.
31. Akkaya N, Akkaya S, Polat Y, et al. Helicobacter pylori seropositivity in fibromyalgia syndrome. Clinical rheumatology. 2011;30(1):43-9.
32. Buskila D, Shnaider A, Neumann L, et al. Fibromyalgia in hepatitis C virus infection. Another infectious disease relationship. Arch Intern Med. 1997;157(21):2497-500.
33. Rivera J, de Diego A, Trinchet M, et al. Fibromyalgia-associated hepatitis C virus infection. British journal of rheumatology. 1997;36(9):981-5.
34. Kozanoglu E, Canataroglu A, Abayli B, et al. Fibromyalgia syndrome in patients with hepatitis C infection. Rheumatol Int. 2003;23(5):248-51.
35. Narvaez J, Nolla JM, Valverde-Garcia J. Lack of association of fibromyalgia with hepatitis C virus infection. The Journal of rheumatology. 2005;32(6):1118-21.
36. Palazzi C, D'Amico E, D'Angelo S, et al. Hepatitis C virus infection in Italian patients with fibromyalgia. Clinical rheumatology. 2008;27(1):101-3.
37. Adak B, Tekeoglu I, Ediz L, et al. Fibromyalgia frequency in hepatitis B carriers. J Clin Rheumatol. 2005;11(3):157-9.
38. Buskila D, Gladman DD, Langevitz P, et al. Fibromyalgia in human immunodeficiency virus infection. The Journal of rheumatology. 1990;17(9):1202-6.
39. Simms RW, Zerbini CA, Ferrante N, et al. Fibromyalgia syndrome in patients infected with human immunodeficiency virus. The Boston City Hospital Clinical AIDS Team. The American journal of medicine. 1992;92(4):368-74.
40. Cruz BA, Catalan-Soares B, Proietti F. Higher prevalence of fibromyalgia in patients infected with human T cell lymphotropic virus type I. The Journal of rheumatology. 2006;33(11):2300-3.
41. Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27.
42. Buskila D, Neumann L, Vaisberg G, et al. Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury. Arthritis Rheum. 1997;40(3):446-52.
43. Wynne-Jones G, Jones GT, Wiles NJ, et al. Predicting new onset of widespread pain following a motor vehicle collision. J Rheumatol. 2006;33(5):968-74.
44. Buskila D, Ablin JN, Ben-Zion I, et al. A painful train of events: increased prevalence of fibromyalgia in survivors of a major train crash. Clin Exp Rheumatol. 2009;27(5 Suppl 56):S79-85.
45. Bazzichi L, Rossi A, Giuliano T, et al. Association between thyroid autoimmunity and fibromyalgic disease severity. Clin Rheumatol. 2007;26(12):2115-20.
46. Aarflot T, Bruusgaard D. Association between chronic widespread musculoskeletal complaints and thyroid autoimmunity. Results from a community survey. Scand J Prim Health Care. 1996;14(2):111-5.
47. Pamuk ON, Cakir N. The frequency of thyroid antibodies in fibromyalgia patients and their relationship with symptoms. Clin Rheumatol. 2007;26(1):55-9.
48. Ribeiro LS, Proietti FA. Interrelations between fibromyalgia, thyroid autoantibodies, and depression. J Rheumatol. 2004;31(10):2036-40.
49. Klein R, Bansch M, Berg PA. Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome. Psychoneuroendocrinology. 1992;17(6):593-8.
50. Loevinger BL, Muller D, Alonso C, et al. Metabolic syndrome in women with chronic pain. Metabolism. 2007;56(1):87-93.
51. Zhou D, Kusnecov AW, Shurin MR, et al. Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis. Endocrinology. 1993;133(6):2523-30.
52. De Maio A. Extracellular heat shock proteins, cellular export vesicles, and the Stress Observation System: a form of communication during injury, infection, and cell damage. It is never known how far a controversial finding will go! Dedicated to Ferruccio Ritossa. Cell Stress Chaperones. 2011;16(3):235-49.
53. Loevinger BL, Shirtcliff EA, Muller D, et al. Delineating psychological and biomedical profiles in a heterogeneous fibromyalgia population using cluster analysis. Clinical rheumatology. 2012;31(4):677-85.
54. Mak TW, Saunders ME. Introduction to the immune response. Chapter 1, Primer to the Immune Response. Academic Cell Update ed. Boston: Elsevier; 2011. p. 3-12.
55. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005;98(4):1154-62.
56. Mak TW, Saunders ME. T cell development activation and effector functions. Chapter 9, Primer to the immune response. Boston: Elsevier; 2011. p. 141-60.
57. Mak TW, Saunders ME. Autoimmune diseases. Chapter 19, Primer to the immune response. Boston: Elsevier; 2011. p. 321-41.
58. Decker T, Muller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol. 2005;5(9):675-87.
59. Mak TW, Saunders ME. Immunity to infection. Chapter 13, Primer to the immune response. Boston: Elsevier; 2011. p. 205-26.
60. Aggarwal BB, Sethi G, Nair A, et al. Nuclear factor-kB: A holy grail in cancer prevention and therapy. Current Signal Transduction Therapy. 2006;1:25-52.
61. Bitzer M, von Gersdorff G, Liang D, et al. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev. 2000;14(2):187-97.
62. Lado-Abeal J, Romero A, Castro-Piedras I, et al. Thyroid hormone receptors are down-regulated in skeletal muscle of patients with non-thyroidal illness syndrome secondary to non-septic shock. Eur J Endocrinol. 2010;163(5):765-73.
63. McKay LI, Cidlowski JA. Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism. Mol Endocrinol. 1998;12(1):45-56.
64. Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis research & therapy. 2008;10(4):212.
65. Gerlo S, Kooijman R, Beck IM, et al. Cyclic AMP: a selective modulator of NF-kappaB action. Cell Mol Life Sci. 2011;68(23):3823-41.
66. Liou JT, Liu FC, Hsin ST, et al. Inhibition of the cyclic adenosine monophosphate pathway attenuates neuropathic pain and reduces phosphorylation of cyclic adenosine monophosphate response element-binding in the spinal cord after partial sciatic nerve ligation in rats. Anesth Analg. 2007;105(6):1830-7.
67. Velazquez KT, Mohammad H, Sweitzer SM. Protein kinase C in pain: involvement of multiple isoforms. Pharmacol Res. 2007;55(6):578-89.
68. Khasar SG, Burkham J, Dina OA, et al. Stress induces a switch of intracellular signaling in sensory neurons in a model of generalized pain. J Neurosci. 2008;28(22):5721-30.
69. Reichling DB, Levine JD. Critical role of nociceptor plasticity in chronic pain. Trends Neurosci. 2009;32(12):611-8.
70. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. The New England journal of medicine. 2005;353(16):1711-23.
71. McKay LI, Cidlowski JA. CBP (CREB binding protein) integrates NF-kappaB (nuclear factor-kappaB) and glucocorticoid receptor physical interactions and antagonism. Mol Endocrinol. 2000;14(8):1222-34.
72. Hole JW. The endocrine system. Chapter 13, Human Anatomy and Physiology. Third ed. Dubuque, Iowa: Wm. C. Brown; 1984. p. 433-73.
73. Van Bogaert T, De Bosscher K, Libert C. Crosstalk between TNF and glucocorticoid receptor signaling pathways. Cytokine Growth Factor Rev. 2010;21(4):275-86.
74. Jeay S, Sonenshein GE, Postel-Vinay MC, et al. Growth hormone prevents apoptosis through activation of nuclear factor-kappaB in interleukin-3-dependent Ba/F3 cell line. Molecular endocrinology. 2000;14(5):650-61.
75. Jones KD, Deodhar P, Lorentzen A, et al. Growth hormone perturbations in fibromyalgia: a review. Semin Arthritis Rheum. 2007;36(6):357-79.
76. Cuatrecasas G, Riudavets C, Guell MA, et al. Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study. BMC Musculoskelet Disord. 2007;8:119.
77. Jones KD, Burckhardt CS, Deodhar AA, et al. A six-month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgia. Arthritis and rheumatism. 2008;58(2):612-22.
78. Ross RL, Jones KD, Bennett RM, et al. Preliminary Evidence of Increased Pain and Elevated Cytokines in Fibromyalgia Patients with Defective Growth Hormone Response to Exercise. Open Immunol J. 2010;3:9-18.
79. Kawashima S, Hayashi M, Takii T, et al. Serotonin derivative, N-(p-coumaroyl) serotonin, inhibits the production of TNF-alpha, IL-1alpha, IL-1beta, and IL-6 by endotoxin-stimulated human blood monocytes. J Interferon Cytokine Res. 1998;18(6):423-8.
80. Mease PJ, Dundon K, Sarzi-Puttini P. Pharmacotherapy of fibromyalgia. Best Pract Res Clin Rheumatol. 2011;25(2):285-97.
81. Traynor LM, Thiessen CN, Traynor AP. Pharmacotherapy of fibromyalgia. Am J Health Syst Pharm. 2011;68(14):1307-19.
82. Audhya T, Adams JB, Johansen L. Correlation of serotonin levels in CSF, platelets, plasma, and urine. Biochimica et biophysica acta. 2012;1820(10):1496-501.
83. Nagaya T, Fujieda M, Otsuka G, et al. A potential role of activated NF-kappa B in the pathogenesis of euthyroid sick syndrome. The Journal of clinical investigation. 2000;106(3):393-402.
84. Tapia G, Fernandez V, Varela P, et al. Thyroid hormone-induced oxidative stress triggers nuclear factor-kappaB activation and cytokine gene expression in rat liver. Free Radic Biol Med. 2003;35(3):257-65.
85. Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol. 2000;68(4):437-46.
86. Nicolson GL. Metabolic syndrome and mitochondrial function: molecular replacement and antioxidant supplements to prevent membrane peroxidation and restore mitochondrial function. J Cell Biochem. 2007;100(6):1352-69.
87. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793-801.
88. Zhang F, Basinski MB, Beals JM, et al. Crystal structure of the obese protein leptin-E100. Nature. 1997;387(6629):206-9.
89. Zhang X, Zhang G, Zhang H, et al. Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell. 2008;135(1):61-73.
90. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab. 2008;19(10):371-9.
91. Green K, Brand MD, Murphy MP. Prevention of mitochondrial oxidative damage as a therpeutic strategy in diabetes. Diabetes. 2004;53(Suppl 1):S110-S8.
92. Bazzichi L, Ciregia F, Giusti L, et al. Detection of potential markers of primary fibromyalgia syndrome in human saliva. Proteomics Clin Appl. 2009;3(11):1296-304.
93. Silverman MN, Heim CM, Nater UM, et al. Neuroendocrine and immune contributors to fatigue. PM & R: the journal of injury, function, and rehabilitation. 2010;2(5):338-46.
94. Liptan GL. Fascia: A missing link in our understanding of the pathology of fibromyalgia. J Bodyw Mov Ther. 2010;14(1):3-12.
95. Sprott H, Muller A, Heine H. Collagen crosslinks in fibromyalgia. Arthritis and rheumatism. 1997;40(8):1450-4.
96. Ruster M, Franke S, Spath M, et al. Detection of elevated Necarboxymethyllysine levels in muscular tissue and in serum of patients with fibromyalgia. Scand J Rheumatol. 2005;34:460-3.
97. Hein G, Franke S. Are advanced glycation end-product-modified proteins of pathogenetic importance in fibromyalgia? Rheumatology (Oxford). 2002;41:1163-7.
98. Bridges D, Thompson SW, Rice AS. Mechanisms of neuropathic pain. Br J Anaesth. 2001;87(1):12-26.
99. De Jongh RF, Vissers KC, Meert TF, et al. The role of interleukin-6 in nociception and pain. Anesth Analg. 2003;96(4):1096-103.
100. Sun J, Ramnath RD, Zhi L, et al. Substance P enhances NF-kappaB transactivation and chemokine response in murine macrophages via ERK1/2 and p38 MAPK signaling pathways. Am J Physiol Cell Physiol. 2008;294(6):C1586-96.
101. Martinez-Lavin M, Solano C. Dorsal root ganglia, sodium channels, and fibromyalgia sympathetic pain. Medical hypotheses. 2009;72(1):64-6
102. Stedman TL. Stedman's medical dictionary. 28th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
103. Vaeroy H, Helle R, Forre O, et al. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain. 1988;32(1):21-6.
104. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis and rheumatism. 1994;37(11):1593-601.
105. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15(2):425-30.